Liqi He
Bristol-Myers Squibb (United States) · 27 works · 525 citations · h-index 9
Top works
- 4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: A Potent, Orally Bioavailable CRF1 Receptor Antagonist
- Non-Peptide Corticotropin-Releasing Hormone Antagonists: Syntheses and Structure−Activity Relationships of 2-Anilinopyrimidines and -triazines
- Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors
- Synthesis and Structure−Activity Relationships of 8-(Pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: Potent, Orally Bioavailable Corticotropin Releasing Factor Receptor-1 (CRF1) Antagonists
- The CRF 1 receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats
- 8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: Selective and Centrally Active Corticotropin-Releasing Factor Receptor-1 (CRF1) Antagonists
- Modulation of cofilin phosphorylation by inhibition of the Lim family kinases
- SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors
- Structure–activity studies on 4-substituted-2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists
- Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology
- Discovery of Novel TLR7 Agonists as Systemic Agent for Combination With aPD1 for Use in Immuno-oncology
- Structure-Based Design of Novel TLR7/8 Agonist Payloads Enabling an Immunomodulatory Conjugate Approach
- Abstract 5417: The identification of BMS-595, an orally active imidazo[1,2-b]pyridazine CK2 inhibitor with in vivo anti-tumor activity
- Discovery of BMS-159, an Orally Active Imidazotriazine Pan-CK2 Inhibitor for the Treatment of Cancer
- Synthesis and biological evaluation of aminoalcohol gambogate as anti-tumor agents
- Supplementary Table S3 from Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors
- Supplementary Table S1 from Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors
- Supplementary Table S1 from Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors
- Supplementary Methods from Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors
- Supplementary Table S3 from Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors